Loading clinical trials...
Loading clinical trials...
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Conditions
Interventions
dalteparin
Locations
42
United States
Arizona Cancer Center
Tucson, Arizona, United States
Bay Area Cancer Research Group
Pleasant Hill, California, United States
Harbor-UCLA Medical Center
Torrance, California, United States
University of CT Health Center
Farmington, Connecticut, United States
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, United States
Georgetown University Hospital-Lombardi Cancer Ctr
Washington D.C., District of Columbia, United States
Start Date
June 1, 2009
Primary Completion Date
March 1, 2012
Completion Date
June 1, 2013
Last Updated
April 18, 2024
NCT06842498
NCT06345508
NCT06316895
NCT06696768
NCT06066138
NCT06898450
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions